PTGER3 Knockdown Inhibits the Vulnerability of Triple-negative Breast Cancer to Ferroptosis

Overview

Journal Cancer Sci

Specialty Oncology

Date 2024 Apr 3

PMID 38566528

Authors

Song Wang

Yueyao Zhang

Dan Zhang

Jie Meng

Na Che

Xiulan Zhao

Tieju Liu

Affiliations

Soon will be listed here.

Abstract

Prostaglandin E receptor 3 (PTGER3) is involved in a variety of biological processes in the human body and is closely associated with the development and progression of a variety of cancer types. However, the role of PTGER3 in triple-negative breast cancer (TNBC) remains unclear. In the present study, low PTGER3 expression was found to be associated with poor prognosis in TNBC patients. PTGER3 plays a crucial role in regulating TNBC cell invasion, migration, and proliferation. Upregulation of PTGER3 weakens the epithelial-mesenchymal phenotype in TNBC and promotes ferroptosis both in vitro and in vivo by repressing glutathione peroxidase 4 (GPX4) expression. On the other hand, downregulation of PTGER3 inhibits ferroptosis by increasing GPX4 expression and activating the PI3K-AKT pathway. Upregulation of PTGER3 also enhances the sensitivity of TNBC cells to paclitaxel. Overall, this study has elucidated critical pathways in which low PTGER3 expression protects TNBC cells from undergoing ferroptosis, thereby promoting its progression. PTGER3 may thus serve as a novel and promising biomarker and therapeutic target for TNBC.

Citing Articles

Identification of E3 ubiquitin ligase-based molecular subtypes and prognostic signature regarding prognosis and immune landscape in bladder cancer.

Hu B, Zhao T, Li Y, Li K, Shen L, Zhu Q Cancer Cell Int. 2025; 25(1):70.

PMID: 40016750 PMC: 11869681. DOI: 10.1186/s12935-025-03703-3.

Study on the Chemical Composition and Anti-Tumor Mechanisms of Fruit By-Products: Based on LC-MS, Network Pharmacology Analysis, and Protein Target Validation.

Zhang Z, Zhang L, Wu P, Tian Y, Wen Y, Xu M Foods. 2024; 13(23).

PMID: 39682950 PMC: 11640417. DOI: 10.3390/foods13233878.

Targeting ferroptosis reveals a new strategy for breast cancer treatment: a bibliometric study.

Liu J, Tang R, Zheng J, Luo K Discov Oncol. 2024; 15(1):679.

PMID: 39560863 PMC: 11576682. DOI: 10.1007/s12672-024-01569-x.

Glutathione-Dependent Pathways in Cancer Cells.

Kalinina E Int J Mol Sci. 2024; 25(15).

PMID: 39125992 PMC: 11312684. DOI: 10.3390/ijms25158423.

PTGER3 knockdown inhibits the vulnerability of triple-negative breast cancer to ferroptosis.

Wang S, Zhang Y, Zhang D, Meng J, Che N, Zhao X Cancer Sci. 2024; 115(6):2067-2081.

PMID: 38566528 PMC: 11145128. DOI: 10.1111/cas.16169.

References

Timmerman L, Holton T, Yuneva M, Louie R, Padro M, Daemen A . Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013; 24(4):450-65. PMC: 3931310. DOI: 10.1016/j.ccr.2013.08.020. View

Nedeljkovic M, Damjanovic A . Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells. 2019; 8(9). PMC: 6770896. DOI: 10.3390/cells8090957. View

Mustacchi G, De Laurentiis M . The role of taxanes in triple-negative breast cancer: literature review. Drug Des Devel Ther. 2015; 9:4303-18. PMC: 4532347. DOI: 10.2147/DDDT.S86105. View

Doll S, Proneth B, Tyurina Y, Panzilius E, Kobayashi S, Ingold I . ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2016; 13(1):91-98. PMC: 5610546. DOI: 10.1038/nchembio.2239. View

Schettini F, Giuliano M, De Placido S, Arpino G . Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. Cancer Treat Rev. 2016; 50:129-141. DOI: 10.1016/j.ctrv.2016.09.004. View

Yao X, Xie R, Cao Y, Tang J, Men Y, Peng H . Simvastatin induced ferroptosis for triple-negative breast cancer therapy. J Nanobiotechnology. 2021; 19(1):311. PMC: 8502296. DOI: 10.1186/s12951-021-01058-1. View

Speckmann B, Bidmon H, Pinto A, Anlauf M, Sies H, Steinbrenner H . Induction of glutathione peroxidase 4 expression during enterocytic cell differentiation. J Biol Chem. 2011; 286(12):10764-72. PMC: 3060527. DOI: 10.1074/jbc.M110.216028. View

Guo C, Li S, Liang A, Cui M, Lou Y, Wang H . PPA1 Promotes Breast Cancer Proliferation and Metastasis Through PI3K/AKT/GSK3β Signaling Pathway. Front Cell Dev Biol. 2021; 9:730558. PMC: 8476924. DOI: 10.3389/fcell.2021.730558. View

Liu Q, Qiao L, Liang N, Xie J, Zhang J, Deng G . The relationship between vasculogenic mimicry and epithelial-mesenchymal transitions. J Cell Mol Med. 2016; 20(9):1761-9. PMC: 4988285. DOI: 10.1111/jcmm.12851. View

10.

Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

11.

Cai J, Ye Z, Hu Y, Ye L, Gao L, Wang Y . Fatostatin induces ferroptosis through inhibition of the AKT/mTORC1/GPX4 signaling pathway in glioblastoma. Cell Death Dis. 2023; 14(3):211. PMC: 10039896. DOI: 10.1038/s41419-023-05738-8. View

12.

Stockwell B, Jiang X . The Chemistry and Biology of Ferroptosis. Cell Chem Biol. 2020; 27(4):365-375. PMC: 7204503. DOI: 10.1016/j.chembiol.2020.03.013. View

13.

Zati Zehni A, Jeschke U, Hester A, Kolben T, Ditsch N, Jacob S . EP3 Is an Independent Prognostic Marker Only for Unifocal Breast Cancer Cases. Int J Mol Sci. 2020; 21(12). PMC: 7352354. DOI: 10.3390/ijms21124418. View

14.

Xu Y, Liu Y, Li K, Yuan D, Yang S, Zhou L . COX-2/PGE2 Pathway Inhibits the Ferroptosis Induced by Cerebral Ischemia Reperfusion. Mol Neurobiol. 2022; 59(3):1619-1631. DOI: 10.1007/s12035-021-02706-1. View

15.

Semmlinger A, von Schoenfeldt V, Wolf V, Meuter A, Kolben T, Kolben T . EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer. BMC Cancer. 2018; 18(1):431. PMC: 5902996. DOI: 10.1186/s12885-018-4286-9. View

16.

Cheuk I, Shin V, Siu M, Tsang J, Ho J, Chen J . Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis. Am J Cancer Res. 2016; 5(11):3389-99. PMC: 4697685. View

17.

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997-4013. DOI: 10.1200/JCO.2013.50.9984. View

18.

Zhai Q, Li H, Sun L, Yuan Y, Wang X . Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis. Breast Cancer. 2019; 26(6):784-791. DOI: 10.1007/s12282-019-00988-x. View

19.

Sanchez T, Moreno J . GR 63799X, an EP3 receptor agonist, induced S phase arrest and 3T6 fibroblast growth inhibition. Eur J Pharmacol. 2005; 529(1-3):16-23. DOI: 10.1016/j.ejphar.2005.10.040. View

20.

Chang-Qing Y, Jie L, Shi-Qi Z, Kun Z, Zi-Qian G, Ran X . Recent treatment progress of triple negative breast cancer. Prog Biophys Mol Biol. 2019; 151:40-53. DOI: 10.1016/j.pbiomolbio.2019.11.007. View